Gene therapy using modified blood stem cells helped five adults with severe hemophilia A reach therapeutic levels of clotting ...

New drugs approved for cardiovascular disease, dermatologic disorders, oncology and more. Nemluvio (nemolizumab-ilto) Interleukin-31 receptor antagonist Treatment of adults and pediatric patients 12 ...

Hinge Bio is committed to developing life-changing medicines for patients with intractable diseases,” said Chief Executive Officer Barry Selick, Ph.D. “These funds will enable early clinical ...

Nemluvio (nemolizumab-ilto) Interleukin-31 receptor antagonist Treatment of adults and pediatric patients 12 years of age and older with moderate to severe atopic dermatitis in combination with ...

A recent study led by MedUni Vienna provides new insights into the mechanisms of coagulation in persons with haemophilia A, the most common form of haemophilia. The research team was able to show that ...

I had no idea who he was. We were on the set of Firebrand, about Henry VIII’s marriage — his sixth and final one — to Katherine Parr. Jude Law was supposed to join them. “Where is he?” ...

The Ministry of Health and Welfare has announced a development program, saying that domestic plasma demand would rise to 170 tonnes next year from 140 tonnes, with growing demand for immunoglobulins, ...

One of these is the load factor. This indicator measures the percentage of available seating capacity filled with passengers. It is released monthly by the International Air Transport Association.

The drug candidate, giroctocogene fitelparvovec, is designed to enable adults with moderately severe to severe hemophilia A to produce Factor VIII. A Phase III trial of the therapy hit its primary ...

Image: Annette Crosbie as Catherine of Aragon, Dorothy Tutin as Anne Boleyn Keith Michell as Henry VIII and Anne Stallybrass as Jane Seymour in a scene from the series The Six Wives Of Henry VIII.

Giroctocogene fitelparvovec is a functioning version of the gene that codes for factor VIII, the clotting protein that’s deficient in hemophilia A patients. The one-time treatment is intended to ...